Clinical trial · Interventional
The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone
NCT04763642CI-TRIAL-00101319completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ampulla of Vater Cancer | Malignant Ampulla of Vater Neoplasm | CURATED_BROADER | 0.80 |
| Bile Duct Cancer | Malignant Bile Duct Neoplasm | CURATED_BROADER | 0.80 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pancreaticoduodenectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Laparoscopic Pancreaticoduodenectomy (LPD)
- interventionNames
- Procedure: pancreaticoduodenectomy
- type
- ACTIVE_COMPARATOR
- label
- Robotic Pancreaticoduodenectomy (RPD)
- interventionNames
- Procedure: pancreaticoduodenectomy
- type
- PLACEBO_COMPARATOR
- label
- Open Pancreaticoduodenectomy (OPD)
- interventionNames
- Procedure: pancreaticoduodenectomy
Primary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age: 21-75 years * Clinically/histologically established diagnosis of the cancer; * Preoperative imaging assessment is resectable or borderline resectable Exclusion Criteria: * Benign tumors of the head of pancreas; * Distant metastasis; * Conversion to laparotomy; * Instrumental findings of the tumor process prevalence; * General somatic status on the ASA III-V scale; * Acute pancreatitis; * Hyperbilirubinemia above 60 μmol/L (3.51 mg/dl) ((normal range, 4-20 μmol/L)). * Patients with intraoperative positive express-histological presence of tumor growth along the border of the pancreas resection
References
Publications (0)
Data not yet available
No reference posted for this study.